O’Melveny Represents Underwriters in US$66 Million Follow-On Public Offering of Sinovac Biotech Ltd.

March 02, 2010

FOR IMMEDIATE RELEASE
Contact:
Erika Tucker
O'Melveny & Myers LLP
213.430.7792      
etucker@omm.com

Lena Li
O'Melveny & Myers LLP
+86 (10) 6563.4282
leli@omm.com

BEIJING, MARCH 3, 2010 – O’Melveny & Myers LLP represented UBS Securities LLC and Piper Jaffray & Co., as joint book-running managers in the US$66 million follow-on public offering of Sinovac Biotech Ltd., a China-based manufacturer of vaccines that protect against infectious diseases, including hepatitis A, hepatitis B and influenza. Sinovac offered 11.5 million common shares at US$5.75 per share, including 1.5 million common shares sold when the underwriters exercised their over-allotment option in full.

 

The O'Melveny team was led by Beijing partner David Roberts, and included associates Hannah Cao (BJ) and Joan Tong (BJ), and legal consultants Jerry Wei (BJ) and Jade Sun (BJ). Counsel Weishi Li (SH) advised on healthcare and intellectual property related matters.  Partner Nate Bush (BJ) and associate Fay Zhou (BJ) advised on regulatory matters. Partner Barbara Stettner (DC) and associate Bjorn Hall (DC) advised on FINRA matters. Partner Larry Sussman (BJ) and associate Cindy Huang (BJ) provided tax advice. Partner Kurt Berney (SH) and counsel Scott Graziano (NB) also helped on certain issues relating to this offering.

 

About O’Melveny & Myers LLP

With approximately 1,000 legal professionals in 14 offices worldwide, O’Melveny & Myers LLP helps industry leaders across a broad array of sectors manage the complex challenges of succeeding in the global economy.  We are a values-driven law firm, guided by the principles of excellence, leadership, and citizenship.  Our commitment to these values is reflected in our dedication to improving access to justice through pro bono work and championing initiatives that increase the diversity of the legal profession.  For more information, please visit www.omm.com or www.omm.cn.